GARDIQUIMOD

GARDIQUIMOD

Biochem/physiol Actions

Gardiquimod is developed as a new imidazoquinoline compound. It stimulates NF-?B (nuclear factor-?B) activation in cells expressing human or murine toll like receptor 7 (TLR7). Gardiquimod is found to be ten times more efficient than imiquimod. It induces splenocyte activation and prevents murine B16 melanoma growth and metastasis. Gardiquimod might serve as a therapeutic agent to prevent HIV-1 (human immunodeficiency virus - 1) transmission. It hinders the life cycle of HIV-1, by blocking the action of HIV-1 reverse transcriptase.

Gardiquimod is a potent and specific agonist for human or mouse Toll-like receptor 7 (TLR7). Also, at high concentration gardiquimod activates TLR8. Similarly to imiquimod, gardiquimod could mimic the effects of viral nucleic acids on the immune system.

Features and Benefits

This compound is featured on the Cytokine Receptors (Interleukin-1 Receptor/TIR Family) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Packaging

5, 25 mg in glass bottle

No detailed specifications are available for this product.

There are no downloads for this product.

Code Description Colour Quality Level Manufacturer Storage Temp. Solubility Form Assay Price Quantity
3574193 GARDIQUIMOD white to beige 100 SIGMA-ALDRICH −20°C
£552.96 (exc VAT) per 25MG
-
+
3574194 GARDIQUIMOD white to beige 100 SIGMA-ALDRICH −20°C
£140.68 (exc VAT) per 5MG
-
+